This was a prospective cohort study including 266,666 participants (60% women) free of cancer, cardiovascular disease, and type 2 diabetes at recruitment from seven European countries in the European ...

Introduction In patients with chronic obstructive pulmonary disease (COPD), the risk of certain cardiovascular (CV) events is increased by threefold to fivefold in the year following acute ...

Discover the definition of communicable diseases, the symptoms of the different types, and how to avoid them here.

Clifton Kirkman II moves through life with an invisible weight on his shoulders — and in his blood. A Detroit-based father, journalist, and patient advocate, Clifton has lived with sickle cell ...

A medical expert warned that the latest Trump administration cuts will prove to be a "significant setback for cell gene therapy."Nicole Verdun, who headed the office that reviews cell and gene ...

He estimated that among adults with Cushing’s syndrome, 20% to 30% have cardiovascular disease, 50% to 90% have hypertension, 40% to 50% have osteoporosis, 20% to 50% have diabetes and 80% to 90 ...

Parkinson's disease, now the fastest-growing neurological disorder, affects over 150,000 Australians—and is increasing at 4% each year." ...

Data reinforce olorofim's potential as a first-in-class treatment for patients with invasive fungal diseases and limited or no antifungal treatment options MANCHESTER, United Kingdom, June 18, 2025 ...

Polyvascular disease, defined as the presence of atherosclerotic disease involving ≥2 vascular beds (coronary, peripheral, or cerebrovascular), is common among patients with PAD and has recently ...

Home-based aerobic exercises, combined with personal coaching, can create an uptake in physical fitness activity for patients with neuromuscular diseases, according to a study published in ...

So too must cardiovascular disease prevention be incorporated into the regulation of cannabis markets. Effective product warnings and education on risks must be developed, required and implemented.

Otsuka Pharmaceutical has shared more detailed data behind its kidney disease drug’s phase 3 win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio (UPCR) levels.